<DOC>
	<DOC>NCT00443846</DOC>
	<brief_summary>Primary objective: To check if RotaTeq® can be administered concomitantly with meningococcal Group C vaccine without impairing the efficacy of MCC vaccine. Secondary objectives: - Efficacy: Additional immunogenicity assessments. - Safety: To describe the safety profile of RotaTeq® and of the MCC vaccine when administered concomitantly with RotaTeq®.</brief_summary>
	<brief_title>RotaTeq® and Meningococcus C Vaccine in Healthy Infants</brief_title>
	<detailed_description />
	<mesh_term>Meningitis</mesh_term>
	<mesh_term>Rotavirus Infections</mesh_term>
	<mesh_term>Meningitis, Meningococcal</mesh_term>
	<criteria>Healthy infants, aged from 6 weeks through full 7 weeks, Consent form signed by at least one parent or by the legal representative properly informed about the study, Parent(s) / legal representative able to understand the protocol requirements and to fill in the Diary Card. History of congenital abdominal disorders, congenital malformation of the gastrointestinal tract that could predispose to intussusception, or abdominal surgery, Congenital fructose intolerance, glucosegalactose malabsorption or sucraseisomaltase insufficiency, Known or suspected impairment of immunological function, Known hypersensitivity to any component of RotaTeq® (e.g. sucrose) or of NeisVacC® (including tetanus toxoid), Prior administration of any rotavirus vaccine, Prior administration of any vaccine within the 28 days prior to randomisation, Fever (rectal temperature ≥38.1°C) and/or acute diarrhoea and/or vomiting at randomisation, History of known prior rotavirus gastroenteritis, chronic diarrhoea, or failure to thrive, Any severe thrombocytopenia or any other coagulation disorder that would contraindicate intramuscular injection, Clinical evidence of active gastrointestinal illness, Receipt of intramuscular, oral, or intravenous corticosteroid treatment within the 14 days prior to randomisation. Note: Infants on inhaled and/or topical steroids may participate in the study, Infants residing in a household with an immunocompromised person, Prior receipt of a blood transfusion or blood products, including immunoglobulins.</criteria>
	<gender>All</gender>
	<minimum_age>42 Days</minimum_age>
	<maximum_age>56 Days</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Prevention of Gastroenteritis due to rotavirus infection. And prevention of Invasive disease caused by Neisseria meningitidis serogroup C.</keyword>
</DOC>